FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1928802301> ?p ?o ?g. }

• W1928802301 endingPage "232" @default.
• W1928802301 startingPage "224" @default.
• W1928802301 abstract "Objectives Although current guidelines recommend resistance testing prior to antiretroviral therapy (ART) reinitiation after treatment interruptions, virological failure of first-line ritonavir-boosted, protease-inhibitor (PI/r)-containing ART is associated with low emergent PI resistance. In patients experiencing unscheduled treatment interruptions (UTrIs) on ritonavir-boosted atazanavir (ATV/r) ART regimens, we hypothesized low emergence of PI mutations conferring resistance to ATV/r. Methods In a retrospective assessment of HIV-infected patients initiating ATV/r-containing ART, using logistic regression we determined factors associated with UTrI, the prevalence of emergent resistance mutations and virological response after ART reinitiation. Results A total of 202 patients [median age 33 years (interquartile range (IQR) 29–40 years); 52% female; median CD4 count 184 cells/μL (IQR 107–280 cells/μL); median HIV RNA 4.6 log10 HIV-1 RNA copies/mL (IQR 3.2–5.1 copies/mL)] initiated ATV/r between 2004 and 2009; 80 (43%) were ART naïve. One hundred and ten patients (55%) underwent 195 UTrIs after a median (IQR) 25 (10–52) weeks on ART, with a median (IQR) UTrI duration of 10 (3–31) weeks. Fifty-four of 110 patients (49%) underwent more than one UTrI. The commonest reasons for UTrI were nonadherence (52.7%) and drug intolerance (20%). Baseline HIV RNA > 100 000 copiesmL [odds ratio (OR) 3.6; 95% confidence interval (CI) 1.3–9.95] and being HCV positive, an injecting drug user or on methadone (OR 2.4; 95% CI 1.3–4.4) were independently associated with UTrI. In 39 patients with at least two resistance assays during UTrIs, 72 new mutations emerged; four nucleoside reverse transcriptase inhibitor (NRTI), two nonnucleoside reverse transcriptase inhibitor (NNRTI) and 66 protease inhibitor (PI) resistance mutations. All emergent PI resistance mutations were minor mutations. At least 65% of patients were re-suppressed on ATV/r reinitiation. Conclusions In this PI-treated cohort, UTrIs are common. All emergent PI resistance mutations were minor and ATV/r retained activity and efficacy when reintroduced, even after several UTrIs, raising questions regarding the need for routine genotypic resistance assays in PI/r-treated patients prior to ART reinitiation after UTrI." @default.
• W1928802301 created "2016-06-24" @default.
• W1928802301 creator A5021195498 @default.
• W1928802301 creator A5026837532 @default.
• W1928802301 creator A5036310952 @default.
• W1928802301 creator A5038000801 @default.
• W1928802301 creator A5068822040 @default.
• W1928802301 creator A5069915892 @default.
• W1928802301 creator A5089570741 @default.
• W1928802301 date "2013-11-12" @default.
• W1928802301 modified "2023-09-27" @default.
• W1928802301 title "Characterization of associations and development of atazanavir resistance after unplanned treatment interruptions" @default.
• W1928802301 cites W1972000638 @default.
• W1928802301 cites W1982733542 @default.
• W1928802301 cites W1997671881 @default.
• W1928802301 cites W1999555849 @default.
• W1928802301 cites W2028731404 @default.
• W1928802301 cites W2029174775 @default.
• W1928802301 cites W2040027667 @default.
• W1928802301 cites W2045131275 @default.
• W1928802301 cites W2045640395 @default.
• W1928802301 cites W2049969210 @default.
• W1928802301 cites W2058078949 @default.
• W1928802301 cites W2064742811 @default.
• W1928802301 cites W2066048934 @default.
• W1928802301 cites W2078862756 @default.
• W1928802301 cites W2084686975 @default.
• W1928802301 cites W2089822517 @default.
• W1928802301 cites W2147210767 @default.
• W1928802301 cites W2155424726 @default.
• W1928802301 cites W2158934554 @default.
• W1928802301 cites W2171236519 @default.
• W1928802301 cites W2319379752 @default.
• W1928802301 doi "https://doi.org/10.1111/hiv.12107" @default.
• W1928802301 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24215370" @default.
• W1928802301 hasPublicationYear "2013" @default.
• W1928802301 type Work @default.
• W1928802301 sameAs 1928802301 @default.
• W1928802301 citedByCount "6" @default.
• W1928802301 countsByYear W19288023012014 @default.
• W1928802301 countsByYear W19288023012016 @default.
• W1928802301 countsByYear W19288023012018 @default.
• W1928802301 countsByYear W19288023012019 @default.
• W1928802301 crossrefType "journal-article" @default.
• W1928802301 hasAuthorship W1928802301A5021195498 @default.
• W1928802301 hasAuthorship W1928802301A5026837532 @default.
• W1928802301 hasAuthorship W1928802301A5036310952 @default.
• W1928802301 hasAuthorship W1928802301A5038000801 @default.
• W1928802301 hasAuthorship W1928802301A5068822040 @default.
• W1928802301 hasAuthorship W1928802301A5069915892 @default.
• W1928802301 hasAuthorship W1928802301A5089570741 @default.
• W1928802301 hasConcept C104317684 @default.
• W1928802301 hasConcept C114851261 @default.
• W1928802301 hasConcept C119060515 @default.
• W1928802301 hasConcept C126322002 @default.
• W1928802301 hasConcept C142462285 @default.
• W1928802301 hasConcept C156719811 @default.
• W1928802301 hasConcept C156957248 @default.
• W1928802301 hasConcept C167135981 @default.
• W1928802301 hasConcept C182707283 @default.
• W1928802301 hasConcept C185592680 @default.
• W1928802301 hasConcept C203014093 @default.
• W1928802301 hasConcept C2777182164 @default.
• W1928802301 hasConcept C2778414717 @default.
• W1928802301 hasConcept C2779298103 @default.
• W1928802301 hasConcept C2993143319 @default.
• W1928802301 hasConcept C3013748606 @default.
• W1928802301 hasConcept C44249647 @default.
• W1928802301 hasConcept C55493867 @default.
• W1928802301 hasConcept C67705224 @default.
• W1928802301 hasConcept C71924100 @default.
• W1928802301 hasConcept C86803240 @default.
• W1928802301 hasConcept C89423630 @default.
• W1928802301 hasConceptScore W1928802301C104317684 @default.
• W1928802301 hasConceptScore W1928802301C114851261 @default.
• W1928802301 hasConceptScore W1928802301C119060515 @default.
• W1928802301 hasConceptScore W1928802301C126322002 @default.
• W1928802301 hasConceptScore W1928802301C142462285 @default.
• W1928802301 hasConceptScore W1928802301C156719811 @default.
• W1928802301 hasConceptScore W1928802301C156957248 @default.
• W1928802301 hasConceptScore W1928802301C167135981 @default.
• W1928802301 hasConceptScore W1928802301C182707283 @default.
• W1928802301 hasConceptScore W1928802301C185592680 @default.
• W1928802301 hasConceptScore W1928802301C203014093 @default.
• W1928802301 hasConceptScore W1928802301C2777182164 @default.
• W1928802301 hasConceptScore W1928802301C2778414717 @default.
• W1928802301 hasConceptScore W1928802301C2779298103 @default.
• W1928802301 hasConceptScore W1928802301C2993143319 @default.
• W1928802301 hasConceptScore W1928802301C3013748606 @default.
• W1928802301 hasConceptScore W1928802301C44249647 @default.
• W1928802301 hasConceptScore W1928802301C55493867 @default.
• W1928802301 hasConceptScore W1928802301C67705224 @default.
• W1928802301 hasConceptScore W1928802301C71924100 @default.
• W1928802301 hasConceptScore W1928802301C86803240 @default.
• W1928802301 hasConceptScore W1928802301C89423630 @default.
• W1928802301 hasIssue "4" @default.
• W1928802301 hasLocation W19288023011 @default.
• W1928802301 hasLocation W19288023012 @default.

• next